Company news

Syndax Pharmaceuticals, Inc. news in 2026

Syndax Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 4, 2026

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

November 4, 2026

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

November 4, 2026

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

November 2, 2026

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

November 2, 2026

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

October 30, 2026

Syndax Announces Participation in November Investor Conferences

October 30, 2026

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

October 26, 2026

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

October 15, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

October 12, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

August 4, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

July 28, 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

July 14, 2026

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

June 11, 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

June 11, 2026

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

June 3, 2026

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

June 2, 2026

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

June 1, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

May 21, 2026

Syndax Announces Participation in Upcoming Investor Conferences

May 20, 2026

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

May 12, 2026

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

April 29, 2026

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

April 24, 2026

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

February 19, 2026

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

February 4, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 4, 2026

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

January 6, 2026

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026